C. Difficile Rates Highest in Northeast Region, Spring Season

Washington, DC, April 28, 2015

Rates of infection with the deadly superbug Clostridium difficile were highest in the Northeast region of the country and in the spring season over the last 10 years, according to a study published in the May issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology (APIC).

Researchers from the University of Texas retrospectively analyzed 2.3 million cases of C. difficile infection (CDI) from 2001-2010 and found the highest incidence in the Northeast (8.0 CDI discharges/1000 total discharges), followed by the Midwest (6.4/1000), South (5.0/1000), and the West (4.8/1000).

Seasonally, spring had the most cases (6.2 CDI discharges/1000 total discharges), followed by winter (5.9/1000), summer (5.9/1000) and fall (5.6/1000). Adults and older adults followed overall trends, whereas pediatric CDI was highest in winter.

CDI mortality was highest in the Midwest (7.3 percent) and among older adults (9.0 percent).

“The peak incidence in the spring could be attributed to increased utilization of antibiotics in winter months,” the authors state. “Prior studies have found a 1 to 2 month lag time between antibiotic exposure and the development of CDI.”

C. difficile causes inflammation of the colon and life-threatening diarrhea. According to the CDC, C. difficile has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess healthcare costs for acute care facilities alone. The CDC estimates that C. difficile caused almost half a million infections in 2011 and that 29,000 U.S. patients died within 30 days of their initial diagnosis.

---

Notes for editors
“Regional and seasonal variation in Clostridium difficile infections among hospitalized patients in the United States, 2001-2010,” by Jacqueline R. Argamany, Samuel L. Aitken, Grace C. Lee, Natalie K. Boyd, and Kelly R. Reveles appears in the American Journal of Infection Control, Volume 43, Issue 5 (May 2015).

Authors details
Jacqueline R. Argamany
Pharmacotherapy Division, College of Pharmacy
University of Texas at Austin, Austin, TX

Samuel L. Aitken, PharmD
Division of Pharmacy
University of Texas MD Anderson Cancer Center, Houston, TX

Grace C. Lee, PharmD
Pharmacotherapy Division, College of Pharmacy
University of Texas at Austin, Austin, TX

Natalie K. Boyd, PharmD, MS
Pharmacotherapy Division, College of Pharmacy
University of Texas at Austin, Austin, TX

Kelly R. Reveles, PharmD, PhD (Corresponding Author)
Pharmacotherapy Division, College of Pharmacy
University of Texas at Austin, Austin, TX

About AJIC: American Journal of Infection Control
AJIC: American Journal of Infection Control (www.ajicjournal.org) covers key topics and issues in infection control and epidemiology. Infection preventionists, including physicians, nurses, and epidemiologists, rely on AJIC for peer-reviewed articles covering clinical topics as well as original research. As the official publication of APIC, AJIC is the foremost resource on infection control, epidemiology, infectious diseases, quality management, occupational health, and disease prevention. AJIC also publishes infection control guidelines from APIC and the CDC. Published by Elsevier, AJIC is included in MEDLINE and CINAHL.

About APIC
APIC’s mission is to create a safer world through prevention of infection. The association’s more than 15,000 members direct infection prevention programs that save lives and improve the bottom line for hospitals and other healthcare facilities. APIC advances its mission through patient safety, implementation science, competencies and certification, advocacy, and data standardization. Visit APIC online at www.apic.org. Follow APIC on Twitter: http://twitter.com/apic and Facebook: www.facebook.com/APICInfectionPreventionandYou. For information: www.apic.org/infectionpreventionandyou

About Elsevier
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Research Intelligence and ClinicalKey— and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries. www.elsevier.com

Media contact
Liz Garman
+1 202 454 2604
egarman@apic.org